Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer symbols : Ltrn save search
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
Published: 2024-04-22 (Crawled : 18:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 6.74%
H: 5.26%
C: 0.35%
lung pharma japan approval cancer cell for trial
Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma
Published: 2023-10-03 (Crawled : 19:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 3.35%
H: 0.0%
C: -11.21%
lp-184 pharma cancer publication research glioblastoma
Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas
Published: 2023-06-26 (Crawled : 18:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 9.18%
H: 0.18%
C: -5.72%
lp-284 drug candidate cancer lymphomas
Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer
Published: 2023-03-28 (Crawled : 13:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 1.53%
H: 0.0%
C: -1.94%
lp-300 lung pharma cancer cell
Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
Published: 2023-03-15 (Crawled : 13:20) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: -0.66%
H: 6.19%
C: 2.43%
pharma research meeting association cancer
Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)
Published: 2022-12-13 (Crawled : 14:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 0.19%
H: 7.56%
C: 1.74%
lp-184 pharma drug candidate breast symposium cancer negative
Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300
Published: 2022-10-20 (Crawled : 12:20) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 1.47%
H: 4.97%
C: -0.83%
lp-300 pharma drug patent candidate cancer
Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.
Published: 2022-09-19 (Crawled : 13:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 0.2%
H: 2.19%
C: 0.0%
treatment pharma cancer
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer
Published: 2022-09-14 (Crawled : 13:20) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 1.57%
H: 8.91%
C: 3.88%
lp-184 pharma conference preclinical positive cancer pancreatic
Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer
Published: 2022-07-14 (Crawled : 13:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 1.88%
H: 1.51%
C: -13.45%
lp-300 fda pharma authorization cancer phase 2
Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting
Published: 2022-03-14 (Crawled : 14:30) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 0.58%
H: 0.0%
C: -9.16%
lp-184 america pos research preclinical positive cancer pre-clinical train brain metastases
Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio
Published: 2022-02-15 (Crawled : 13:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 1.39%
H: 3.65%
C: 3.65%
health research collaboration cancer children
Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 2.48%
H: 0.0%
C: -11.41%
lp-100 solid tumors ces announces collaboration drug research 100 collaboration cancer
Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 20:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 0.13%
H: 1.57%
C: -1.77%
lp-284 ema positive cancer
Lantern Pharma to Host Virtual KOL Event on the Potential Treatment of Pancreatic Cancer with Drug Candidate LP-184 on November 18th, World Pancreatic Cancer Day
Published: 2021-11-12 (Crawled : 15:00) - prnewswire.com
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: -3.14%
H: 0.0%
C: 0.0%
treatment potential cancer drug pancreatic
Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-11-04 (Crawled : 15:15) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 0.19%
H: 2.23%
C: -1.15%
presentation ema cancer
Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer
Published: 2021-09-28 (Crawled : 14:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 2.8%
H: 0.34%
C: -10.23%
partnership phase 2 lung cancer collaboration cancer trial enroll
Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer
Published: 2021-08-16 (Crawled : 14:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: -0.71%
H: 1.76%
C: -4.32%
presentation cancer conference pancreatic pancreas
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
Published: 2021-08-11 (Crawled : 13:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 10.01%
H: 0.41%
C: -11.34%
treatment fda cancer drug pancreatic pancreas granted grant designation pharma
Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S
Published: 2021-07-27 (Crawled : 22:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 0.62%
H: 1.32%
C: -2.48%
phase 2 commercialization prostate cancer cancer trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.